Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells with an inhibitory concentration (IC 50) of 2.62 µM, promoting apoptosis and cell cycle arrest by disrupting the RAS/PI3K/Akt/JNK signaling pathways [1].

Antitumor agent-86, administered at concentrations ranging from 0-200 μM for 48 hours, dose-dependently suppresses proliferation in MCF-7, MDA-MB-231, Caco-2, and PANC-1 cancer cell lines, with respective IC50 values of 2.617, 6.778, 14.8, and 23.58 μM [1]. At a concentration of 2.62 μM over 48 hours, it induces apoptosis, cell cycle arrest, reduces levels of p-RAS protein in MCF-7 cells, decreases mRNA transcription levels of PI3K and Akt, and lowers the expression of p-JNK protein [1]. Furthermore, Antitumor agent-86 upregulates the expression of the p21 gene at the same concentration and duration [1].